Skip to main content
OpenTrials
Completed

NCT Number: NCT03706235

Colvera for Detection of Disease Recurrence

To compare the sensitivity and specificity estimates of Colvera with that of a commercially available CEA test for detection of recurrent disease in CRC subjects who are undergoing surveillance for recurrence.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Torrance Memorial Physician Network, Redondo Beach, California, United States

Loading trial locations.

About this study

This is an observational, prospective comparison study, where blood is collected for assay of methylated BCAT1 and IKZF1 DNA and CEA, from subjects who have undergone curative treatment for primary CRC of stages II and III (AJCC) and who are in remission and scheduled for follow-up radiological imaging as part of their surveillance program for recurrence. Participation is for one visit only as part of each subject's surveillance-monitoring schedule. Two K2-EDTA blood tubes and two PAXgene™ tubes will be collected Any evidence of methylated BCAT1 and/or IKZF1 DNA in blood represents a Colvera "positive" result. CEA levels of 5ug/L or higher will represent a "positive" result. Sensitivity and specificity of the Colvera and CEA test will be estimated and compared in a paired fashion in each case where recurrence status has been investigated and determined by the site clinical management team. Blood testing shall be performed and analyzed by qualified staff blinded to clinical status. This is a cross-sectional observational non-significant risk study, and test results will not be used for clinical management, i.e. there will be no interventions in subjects consenting to participate in this Research Study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is 18 years or older, and capable and willing to provide informed consent.
  • Subject has undergone curative treatment for primary CRC of stages II and III (AJCC).
  • Subject has no clinical evidence of disease (NED) (after initial treatment)
  • Subject has concluded course of initial treatment for primary CRC (i.e. end of surgery, chemotherapy and/or radiotherapy)
  • Subject is willing/able to provide a blood sample

Exclusion criteria

  • Subject has evidence of residual disease.
  • Subject has other organ cancer at the time of recruitment.
  • Subject has prior history of recurrent CRC.
  • Subject has concurrent serious non-neoplastic illness that makes enrollment impractical or clinically inappropriate.
  • Subject is receiving chemo- or radiotherapy at the time of blood collection, or between blood collection and radiological imaging.

Treatment and study plan

Blood draw (venipuncture)

Other

Draw 40 mls of blood from eligible subjects. Process and ship samples to sponsor.

Primary outcomes

  1. Sensitivity, specificity, positive predictive value and negative predictive value

    Time frame: 1.5 years

    on positive or negative Colvera and CEA test results

Sponsors and collaborators

Lead sponsor

Clinical Genomics Pathology

Industry

Registry information

Official study title

Evaluation of the Performance of the Clinical Genomics Colvera Test in the Detection of Disease Recurrence in Patients Diagnosed With Colorectal Cancer- "NOVA"

Acronym: NOVA

Important dates

Study start
2018
Primary completion
2019
Study completion
2020
First posted
Oct 15, 2018
Registry last updated
Jul 14, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.